849744-89-4

Upstream product

• 588728-65-8 [(2S,3S,6R)-6-Allyl-2-[2-(tert-butyl-dimethyl-silanyloxy)-1,1-dimethyl-ethyl]-3-hydroxy-2-methoxy-tetrahydro-pyran-(4E)-ylidene]-acetic acid methyl ester 
• 478242-82-9 [(2S,6R)-6-Allyl-2-[2-(tert-butyl-dimethyl-silanyloxy)-1,1-dimethyl-ethyl]-2-methoxy-3-oxo-tetrahydro-pyran-(4E)-ylidene]-acetic acid methyl ester 
• 849744-81-6 3-Nitro-benzoic acid (2S,3S,6R)-6-allyl-2-(1,1-dimethyl-2-oxo-ethyl)-2-methoxy-4-[1-methoxycarbonyl-meth-(E)-ylidene]-tetrahydro-pyran-3-yl ester 
• 849744-85-0 3-Nitro-benzoic acid (2S,3S,6S)-6-(2,3-bis-triethylsilanyloxy-propyl)-2-(1,1-dimethyl-2-oxo-ethyl)-2-methoxy-4-[1-methoxycarbonyl-meth-(E)-ylidene]-tetrahydro-pyran-3-yl ester 
• 849744-77-0 3-Nitro-benzoic acid (2S,3S,6R)-6-allyl-2-[2-(tert-butyl-dimethyl-silanyloxy)-1,1-dimethyl-ethyl]-2-methoxy-4-[1-methoxycarbonyl-meth-(E)-ylidene]-tetrahydro-pyran-3-yl ester 

Relevant academic research and scientific papers

Identification of a tunable site in bryostatin analogs: C20 bryologs through late stage diversification

The C20 region of our bryostatin analogs was identified as a nonpharmacophoric site that could be varied to tune analogs for function and physical properties without significantly affecting their binding affinity for PKC. The use of this site in a late-stage diversification strategy has enabled the facile synthesis of a variety of new C20 analogs, all of which retain nanomolar affinity for PKC, in agreement with our pharmacophore hypothesis.